- Home
- PFO vs PBYI Comparison
PFO vs PBYI Comparison
Compare PFO & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFO
- PBYI
- Stock Information
- Founded
- PFO 1991
- PBYI 2010
- Country
- PFO United States
- PBYI United States
- Employees
- PFO N/A
- PBYI N/A
- Industry
- PFO Finance Companies
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- PFO Finance
- PBYI Health Care
- Exchange
- PFO Nasdaq
- PBYI Nasdaq
- Market Cap
- PFO 123.7M
- PBYI 126.5M
- IPO Year
- PFO N/A
- PBYI N/A
- Fundamental
- Price
- PFO $9.02
- PBYI $2.90
- Analyst Decision
- PFO
- PBYI Strong Buy
- Analyst Count
- PFO 0
- PBYI 1
- Target Price
- PFO N/A
- PBYI $7.00
- AVG Volume (30 Days)
- PFO 31.8K
- PBYI 566.4K
- Earning Date
- PFO 01-01-0001
- PBYI 11-07-2024
- Dividend Yield
- PFO 6.51%
- PBYI N/A
- EPS Growth
- PFO N/A
- PBYI 492.79
- EPS
- PFO N/A
- PBYI 0.47
- Revenue
- PFO N/A
- PBYI $243,569,000.00
- Revenue This Year
- PFO N/A
- PBYI N/A
- Revenue Next Year
- PFO N/A
- PBYI N/A
- P/E Ratio
- PFO N/A
- PBYI $6.24
- Revenue Growth
- PFO N/A
- PBYI 6.30
- 52 Week Low
- PFO $6.90
- PBYI $2.23
- 52 Week High
- PFO $8.51
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- PFO 32.67
- PBYI 51.31
- Support Level
- PFO $9.05
- PBYI $2.32
- Resistance Level
- PFO $9.18
- PBYI $3.25
- Average True Range (ATR)
- PFO 0.11
- PBYI 0.32
- MACD
- PFO -0.02
- PBYI -0.03
- Stochastic Oscillator
- PFO 3.33
- PBYI 48.74
About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end investment company. Its primary investment objective is to produce high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.